Content ID

46994

Bayer buys Icon Genetics

Bayer Innovation, a subsidiary of the Bayer Group, has acquired Icon Genetics AG, a biotech company headquartered in Munich, Germany. Icon Genetics discovers innovative methods for the development and use of engineered plants.

The companies have agreed not to disclose any details of the acquisition, which closed on Monday.

Bayer and Icon Genetics have been cooperating on research since January of 2005. The previously announced alliance centered around the use of Icon's proprietary magnICON® biomanufacturing platform technology, which produces therapeutic and other high-value recombinant proteins in non-food plants.

Bayer says the acquisition will strengthen its effors to produce specific plant-made pharmaceuticals. The technology uses the natural protein production processes in plants as a way of producing therapeutically active substances.

Bayer Innovation, a subsidiary of the Bayer Group, has acquired Icon Genetics AG, a biotech company headquartered in Munich, Germany. Icon Genetics discovers innovative methods for the development and use of engineered plants.

Read more about
Loading...

Tip of the Day

Driver for electric fence posts is helpful

Fence post driver from Mar '20 AATF I welded a steel cap and handle onto one end of a section of light-duty 1¼-inch angle iron and a footstep onto the other end. This lets me... read more

Talk in Marketing